基于网络药理学的乳香-没药药对药效机制研究＊

目的 网络药理学方法,研究乳香-没药药对在抗溃疡、抗炎、抗肿瘤和炎症性肠病和镇痛的治疗过程中的共性作用机制。方法 借助中药系统药理学分析平台（TCMSP）检索乳香-没药药对的化学成分和作用靶点,通过人类基因数据库(Genecards)和在线人类孟德尔遗传数据库(OMIM)等多个数据库筛选上述5种疾病相关靶点。利用 Cytoscape3.7.1 软件构建“药物-靶点-疾病”交互网络图。运用蛋白相互作用（PPI）筛选核心靶点;通过生物学信息注释数据库（DAVID）做基因本体（GO）功能分析和基因组百科全书（KEGG）通路分析。结果 乳香-没药药对共包含403个化合物,247个活性靶点,与五种疾病基因交集获得79个高频基因,通过构建“药物-靶点-疾病”网络及对网络进行分析,共获得20个关键靶标;在对GO富集分析时,获得8个高频共性相关条目,主要病毒感染和肿瘤信号通路等;在对靶标进行KEGG通路分析时,共获得6条高频相关的通路,其中病毒感染和肿瘤信号通路为主要通路。结论 本研究结果初步验证了乳香-没药药对在抗溃疡、抗炎、抗肿瘤、炎症性肠病和镇痛这五种疾病治疗的作用机制以及高频共性靶点、基因、信号通路等,为进一步阐述乳香-没药药对作用机制奠定了良好的理论基础。

Study on the Efficacy Mechanism of Frankincense-Myrrha Herbal Pair Based on Network Pharmacology

Objective To explore the mechanism of network pharmacology of frankincense and myrrh in anti-ulcer, anti-inflammation, anti-cancer, inflammatory bowel disease and analgesic treatment.Methods Frankincense and myrrh pair active ingredients` relevant chemical structure and corresponding drug targets were obtained by the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP); Five diseases related targets were screened by Online Mendelian Inheritance in Man (OMIM) and The Human Gene Database (GeneCards); The "drug-gene-disease" networks were constructed by Cytoscape 3.7.1; The core targets were screened by Protein-Protein Interaction Networks (PPI); Gene Ontology (GO) function enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment were analyzed by the Database for Annotation, Visualization and Integrated Discovery (DAVID).Results We concluded that the volatile oil components were the main chemical component by "herb-gene-drug" networks, and 20 high frequency common targets, 8 high frequency common entries and 6 KEGG high frequency common path ways were obtained at the same time.Conclusion The common mechanisms of frankincense and myrrh pair in anti-ulcer, anti-inflammation, anti-cancer, inflammatory bowel disease, analgesia, common high frequency targets, genes and KEGG pathways discovered by network pharmacological methods provide theoretical basis experimental date for further research and clinical application of frankincense active ingredients.